The endocannabinoid anandamide downregulates IL-23 and IL-12 subunits in a viral model of multiple sclerosis: Evidence for a cross-talk between IL-12p70/IL-23 axis and IL-10 in microglial cells
Authors:
- Leyre MestreLMLeyre Mestre
- Frida LoríaFLFrida Loría
- Fabian DocagneFDFabian Docagne
- Carmen GuazaCGCarmen Guaza
- 1 May 2011
- journal article
- Published by Elsevier in Brain, Behavior, and Immunity
- Vol. 25 (4) , 736-749
Abstract
No abstract availableKeywords
Funding Information
- Spanish Ministerio de Educación y Ciencia (SAF 2007/60038)
- Comunidad Autónoma de Madrid (CAM) (S/SAL0261/2006)
- Red Española de Esclerosis Múltiple (RD07/0060; REEM; RETICS; ISCIII)
This publication has 69 references indexed in Scilit:
- IL-10 within the CNS is necessary for CD4+ T cells to mediate neuroprotectionBrain, Behavior, and Immunity, 2011
- 99th Dahlem Conference on Infection, Inflammation and Chronic Inflammatory Disorders: Epstein–Barr virus and multiple sclerosis: epidemiological evidenceClinical and Experimental Immunology, 2010
- Endocannabinoid signaling in microglial cellsNeuropharmacology, 2009
- Endocannabinoids and the Brain Immune System: New Neurones at the Horizon?Journal of Neuroendocrinology, 2008
- CB2 cannabinoid receptors as an emerging target for demyelinating diseases: from neuroimmune interactions to cell replacement strategiesBritish Journal of Pharmacology, 2008
- Therapeutic potential of CB2 targeting in multiple sclerosisExpert Opinion on Therapeutic Targets, 2008
- Anti-IL-23 therapy inhibits multiple inflammatory pathways and ameliorates autoimmune encephalomyelitisJournal of Clinical Investigation, 2006
- IL-23 is essential for T cell–mediated colitis and promotes inflammation via IL-17 and IL-6Journal of Clinical Investigation, 2006
- Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cellsNature, 2006
- Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brainNature, 2003